Home › Funds › Life Cycle Investment Partners Ltd › VRTX

Life Cycle Investment Partners Ltd position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Life Cycle Investment Partners Ltd reported holding 505,070 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$264.1M, representing 1.12% of its reported portfolio and ranking #28 among its reported holdings. Life Cycle Investment Partners Ltd has disclosed VRTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)505.07K sh
Reported value held$264.06M
Portfolio Weight1.12%
First reportedQ4 2025
Last changeReduce
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Life Cycle Investment Partners Ltd's VRTX position evolved

Life Cycle Investment Partners Ltd first disclosed a stake in VRTX in Q4 2025 at 366,854 shares (US$166.3M). The position peaked in Q3 2026 at 505,070 shares, worth US$264.1M. Across 4 filings, Life Cycle Investment Partners Ltd increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 505,070 shares valued at US$264.1M — a reduction of -9,109 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2025 366.85K $166.32M New
Q1 2026 440.41K $196.66M Add
Q2 2026 514.18K $255.41M Add
Q3 2026 505.07K $264.06M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Life Cycle Investment Partners Ltd held VRTX?

Life Cycle Investment Partners Ltd has disclosed VRTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Life Cycle Investment Partners Ltd's current position in VRTX?

As of Q3 2026, Life Cycle Investment Partners Ltd holds 505.07K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $264.06M, representing 1.12% of its reported portfolio and ranking #28.

Has Life Cycle Investment Partners Ltd been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Life Cycle Investment Partners Ltd reduced its position in VRTX. The position peaked in Q3 2026 at 505.07K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.